Skip to Content
Merck
CN

Key Documents

View All Documentation

53561-U

Ascentis® Express Peptide 160 Å ES-C18 (2.7 μm) HPLC Columns

L × I.D. 15 cm × 1 mm HPLC Capillary Column

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

UNSPSC Code:
41115700
eCl@ss:
32110501
NACRES:
SB.52
L × i.d.:
15 cm × 1 mm
Particle size:
2.7 μm
Matrix active group:
C18 (octadecyl) phase
Pore size:
160 Å
Matrix:
Fused-Core particle platform, superficially porous particle
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Ascentis® Express Peptide ES-C18, 2.7 μm Capillary HPLC Column, 2.7 μm particle size, L × I.D. 15 cm × 1 mm

Quality Level

100

material

stainless steel column

agency

suitable for USP L1

product line

Ascentis®

feature

endcapped: no

manufacturer/tradename

Ascentis®

packaging

1 ea of

parameter

≤100 °C temp. range

technique(s)

HPLC: suitable, LC/MS: suitable, UHPLC-MS: suitable, UHPLC: suitable

L × I.D.

15 cm × 1 mm

surface area

90 m2/g

impurities

<5 ppm metals

matrix

Fused-Core particle platform, superficially porous particle

matrix active group

C18 (octadecyl) phase

particle size

2.7 μm

pore size

160 Å

pH range

1-9

separation technique

reversed phase

Legal Information

Ascentis is a registered trademark of Merck KGaA, Darmstadt, Germany

Still not finding the right product?

Explore all of our products under Ascentis® Express Peptide ES-C18, 2.7 μm Capillary HPLC Column

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
USNVB001273
USNVB001269
USNVB001268
USNVB001267
USNVB001265

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Protocols

阿达木单抗（adalimumab）肽图谱 LC-MS/MS 分析工作流程

基于优化的 LC-MS/MS 工作流程，通过过滤辅助样品制备 (FASP) 对阿达木单抗 (Humira) 绘制低伪影胰蛋白酶酶解和肽图谱。

Peptide Mapping LC-MS/MS Analysis Workflow for Adalimumab

An optimized LC-MS/MS based workflow for low artifact tryptic digestion and peptide mapping of monoclonal antibody, adalimumab (Humira) using filter assisted sample preparation (FASP).

Articles

Ascentis® Express Peptide ES-C18 U/HPLC Columns

Choose Ascentis® Express Peptide ES-C18 U/HPLC Columns based on Fused-Core® technology for fast and efficient separation of high-molecular weight compounds, such as peptides and small proteins. With a 2.7 µm particle size and rigorous testing, these columns offer reliable results and high efficiency.

Quality Attribute Determination of Monoclonal Antibodies

Workflows for monoclonal antibody adalimumab characterization ensure drug safety and efficacy through critical quality attribute analysis.

Related Content

Ascentis Express Nano/Capillary Column Care and Use Sheet

Ascentis® Express Nano/Capillary Column Care & Use Sheet

Meiyun Shi et al.
Journal of separation science, 38(8), 1351-1357 (2015-01-30)
The pentapeptide thymopentin (Arg-Lys-Asp-Val-Tyr, RKDVY) corresponds to amino acids 32-36 of the 49 amino acid immunomodulatory polypeptide, thymopoietin, whose biological activity is partially reproduced. Thymopentin is widely used in the clinic and represents a promising target for drug design but
E Lesellier
Journal of chromatography. A, 1266, 34-42 (2012-11-03)
The recent introduction of new stationary phases for liquid chromatography based on superficially porous particles, called core-shell or fused-core, dramatically improved the separation performances through very high efficiency, due mainly to reduced eddy diffusion. However, few studies have evaluated the
C Gröer et al.
Journal of pharmaceutical and biomedical analysis, 100, 393-401 (2014-09-15)
Cytochrome P450 (CYP) enzymes and UDP-glucuronosyltransferases (UGT) are major determinants in the pharmacokinetics of most drugs on the market. To investigate their impact on intestinal and hepatic drug metabolism, we developed and validated quantification methods for nine CYP (CYP1A2, CYP2B6

Global Trade Item Number

SKUGTIN
53561-U04061838531513